Overview

Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery

Status:
Active, not recruiting

Trial end date:
2021-05-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving arsenic trioxide and temozolomide together with radiation therapy after surgery may kill any remaining tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of arsenic trioxide and temozolomide when given together with radiation therapy and to see how well they work in treating patients with malignant glioma that has been removed by surgery.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Northwestern University

Collaborators:

Cephalon
CTI BioPharma

Treatments:

Arsenic Trioxide
Dacarbazine
Temozolomide